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Background: Metabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with car- 
diovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to 
metabolic risk factors. 
Methods: We measured 154 circulating lipid species in 658 participants from the Framingham Heart 
Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with 
obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent 
cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal 
changes in metabolic risk factors. 
Results: Thirty-nine lipids were associated with obesity and eight with dysglycemia in the FHS. Of 32 
lipids that were available for replication for obesity and six for dyslipidemia, 28 (88%) replicated for 
obesity and ﬁve (83%) for dysglycemia. Four lipids were associated with longitudinal changes in body 
mass index and four were associated with changes in fasting blood glucose in the FHS. 
Conclusions: We identiﬁed and replicated several novel lipid biomarkers of key metabolic traits. The lipid 
moieties identiﬁed in this study are involved in biological pathways of metabolic risk and can be explored 
for prognostic and therapeutic utility. 
Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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c  Research in context 
Evidence before this study 
Prior metabolomic association studies linking lipids with
metabolic risk factors have been limited by the lipid metabolites
proﬁled, lack of independent external replication, and absence of
longitudinal association analyses. 
Added value of this study 
Our global lipidomics approach, along with external replication
in three independent cohorts, provides robust cross-sectional as-
sociations of several lipid moieties with obesity and dysglycemia.
We further strengthen these results by identifying lipids associated
with longitudinal changes in metabolic risk factors. 
Implications of all the available evidence 
Our results, taken together with prior evidence, highlight lyso-
glycerophospholipids and dihydrosphingolipids as markers of obe-
sity and dysglycemia that should be explored for prognostic and
therapeutic utility. 
1. Introduction 
Cardiovascular disease (CVD), the leading cause of mortality
in the United States and worldwide, accounts for roughly 30% of
deaths [1] and is closely linked to the burden of metabolic risk
factors. Metabolic syndrome (MetS) [2] , clinically deﬁned as the si-
multaneous presence of several metabolic risk factors [3] , affects
over 20% of American adults and is associated with a doubling in
CVD risk [4] . While MetS is treated using lifestyle and drug-based
interventions, its pathogenesis is not fully understood. Identifying
key mechanistic drivers of metabolic risk factors and the progres-
sion from subclinical to overt disease may allow for the develop-
ment of more targeted and effective interventions. The complexi-
ties of the associated metabolic risk factors necessitate global ap-
proaches, such as lipidomic proﬁling, which has advanced in the
past decade due to mass spectrometry [5] . Considerable CVD re-
search has shifted towards interrogating the circulating lipidome
to further understand the cardiovascular consequences of dysregu-
lated lipid metabolism [6] . 
Here, we report the results of plasma lipidomic proﬁling via
liquid chromatography-tandem mass spectrometry (LC-MS/MS) in
Framingham Heart Study (FHS) participants [ 7 , 8 ] in whom cross-
sectional and longitudinal phenotypic characterization are avail-
able. Independent external replication of all cross-sectional asso-
ciations from discovery was sought in the Erasmus Rucphen Fam-
ily (ERF) study [9] , San Antonio Family Heart Study (SAFHS) [10] ,
and Progression of Early Subclinical Atherosclerosis (PESA) study
[11] . We posited that the characteristic metabolic traits that de-
ﬁne MetS have distinct and shared lipidomic signatures. To that
end, we sought to identify lipid metabolomic biomarkers associ-
ated with metabolic risk factors to further understand the biology
underlying MetS and to highlight high-value targets for the treat-
ment and prevention of cardiometabolic disease. action monitoring; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PESA, 
Progression of Early Subclinical Atherosclerosis; PS, phosphatidylserine; SAFHS, San 
Antonio Family Heart Study; SL, sphingolipid; SM, sphingomyelin; T2DM, type II di- 
abetes mellitus; TAG, triacylglycerol. 
∗ Corresponding author: National Heart, Lung, and Blood Institute, Population Sci- 
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.1. Study samples 
The discovery study sample included participants from the Off-
pring ( n = 5124) and Third Generation ( n = 4095) FHS cohorts
6,7). FHS clinical evaluations, including physical examinations and
aboratory tests, were conducted every four to eight years. We
ampled FHS Offspring cohort participants evaluated at Examina-
ion 8 (20 05–20 08; n = 3021) and Third Generation cohort partic-
pants evaluated at Examination 1 (20 02–20 05; n = 4095). Exclu-
ion criteria included the following: off-site examination ( n = 107),
o blood specimen ( n = 126), lack of unrestricted consent ( n = 335),
revalent CVD at baseline ( n = 216), pharmacological treatment for
iabetes ( n = 257) or dyslipidemia ( n = 1201), missing BMI data
 n = 4), cigarette smoking at the time of examination ( n = 772), and
ge < 50 or > 79 years in the Offspring cohort ( n = 123) or age < 25
r > 59 years in the Third Generation cohort ( n = 183). The ﬁnal
tudy sample was selected from 3792 eligible participants. 
Independent external replication was conducted in the ERF
tudy, SAFHS, and PESA study. The ERF study is a prospective
amily-based study consisting of 3465 individuals aged 17–92 years
rom the southwest region of the Netherlands recruited based on
inship [ 9 , 12 ]. Samples without measures of metabolites or fasting
lucose, or available genotype data for family kinship adjustment
ere excluded. The ﬁnal study sample consisted of 2564 partic-
pants without diabetes. All baseline demographic data was col-
ected between 20 02 and 20 06, and venous blood samples were
ollected after at least eight hours of fasting. A more detailed de-
cription of the ERF study and baseline characteristics of the study
ample have been reported previously [9] 
The SAFHS is a population-based, epidemiological study of type
I diabetes (T2D) mellitus and CVD in Mexican Americans and non-
ispanic whites [ 10 , 13 , 14 ]. A total of 1431 individuals comprising
2 extended families who had given informed consent underwent
lood sample collection. Of these, plasma samples from 1076 par-
icipants had complete data and were used for lipidomic proﬁl-
ng via liquid chromatography electrospray ionization tandem mass
pectrometry (LC ESI-MS/MS) [13] . 
The PESA study is an observational cohort study of subclinical
therosclerosis in 4184 middle-aged (40–54 years) employees at
anco Santander in Madrid, Spain [11] . Recruitment began in 2010,
nd the baseline examination, including assessment for CVD risk
actors and blood sampling, was completed in 2013. PESA partici-
ants with prevalent CVD at baseline ( n = 34), active treatment for
ancer ( n = 2), history of transplants requiring active immunother-
py ( n = 2), morbid obesity (BMI ≥40 kg/m 2 ) ( n = 22), chronic kid-
ey disease (glomerular ﬁltration rate ˂60 mL/min per square me-
er) ( n = 1), an implanted metal device that could produce artifacts
n computed tomography ( n = 2), and any limitation or disability
esulting in failure to comply with the study protocol ( n = 1) were
xcluded. The ﬁnal PESA sample size included 4120 participants. 
.2. Clinical measures 
For the cross-sectional analyses, we evaluated three
ategorically-deﬁned metabolic risk factors: obesity (BMI
30 kg/m 2 ), dysglycemia (fasting blood glucose ≥100 mg/dL
adjusted for diabetes medications as described below]), and dys-
ipidemia (TAG ≥ 150 mg/dL [adjusted for lipid-lowering treatment
s described below] or HDL cholesterol [HDL-C] < 40 mg/dL in
en or < 50 mg/dL in women). All deﬁnitions were obtained from
he National Cholesterol Education Program’s Adult Treatment
anel III report [19] . For the longitudinal analyses, serial changes
from the baseline examination to the follow-up examination) in
he continuous measures of the above-mentioned metabolic risk
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Fig. 1. Flow chart of experimental design. 
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e  actors were used as the outcomes. The continuous measures for
besity, dysglycemia, and dyslipidemia were BMI [kg/m 2 ], fasting
lood glucose [mg/dL], and TAG [mg/dL] and HDL-C [mg/dL],
espectively. 
.3. Study design 
A 2 ×2 ×2 factorial study design was used in the FHS to group
amples according to the presence or absence of each of the three
entral metabolic risk factors. Based on the clinical cut-points de-
cribed above, eight (2 ×2 ×2 = 8) mutually-exclusive groups were
enerated from the three dichotomized outcomes. 80–84 individ-
als were selected for each group while controlling for sex and
ohort across all groups. The longitudinal study sample consisted
f all FHS participants in the cross-sectional sample who attended
he subsequent clinic examination and had complete follow-up
ata for the traits of interest ( n = 554). For those on lipid-lowering
 n = 133) or diabetes medications ( n = 30) at follow-up, observed
alues were also adjusted for treatment effects (see Statistical
ethods for details). Fig. 1 provides a ﬂow chart so the experi-
ental design can be visualized. 
.4. Lipidomic proﬁling 
Lipidomic proﬁling for replication was carried out via three dif-
erent platforms – 1) liquid chromatography-mass spectrometry 
LC-MS), 2) AbsoluteIDQ p150 Kit of Biocrates Life Sciences AG,
nd 3) electrospray-ionization mass spectrometry (ESI-MS) – using
ethods previously described [15–18] 
A detailed description of the LC-MS based lipidomic proﬁling
ethods used in the FHS is provided in the Supplementary Text
nd Table 2 a contains the metabolite transitions used in the MRM
ass spectrometry. 
.5. Statistical methods 
Statistical analyses were performed with SAS software version
.2 (SAS Institute, Inc., Cary, NC, USA). All lipid measurements were
ank-normalized via the Blom method [20] . For the FHS cross-
ectional analyses, we used generalized linear mixed models (SAS
rocedure: GLIMMIX) to identify lipid species that (a) differed
cross all eight metabolic risk factor groups and (b) were associ-
ted with individual risk factors. All analyses were adjusted for theollowing baseline covariates: age, sex, cohort, and age-cohort in-
eraction. To identify lipid-level associations across all eight groups,
ach lipid marker was treated as the outcome variable and the
ight-level risk group as the main predictor. That is, our models
ere lipid level ~ cohort age sex cohort ∗age risk-factor-classes ( ∗
evels). 
To identify independent associations between lipid levels and
etabolic risk factors, each lipid marker was considered as the
utcome variable and each risk factor as the main predictor with
he other two risk factors as covariates. That is, our models were
ipid level ~ cohort age sex cohort ∗age obesity dysclycemia dys-
ipidemia, where cohort, sex, obesity, dysclycemia and dyslipidemia
re binary variables. 
Secondary analyses of the dyslipidemia axis were conducted us-
ng the same models to explore independent associations between
ipid species and high versus low TAG and HDL-C. In the PESA
amples, generalized linear mixed models were used to identify
ipid associations across all eight risk factor groups and with obe-
ity, dysglycemia, and dyslipidemia. All replication models were
djusted for sex and baseline age. In addition, for individuals in
he PESA cohort with self-reported use of lipid-lowering or dia-
etes medications, values were adjusted for treatment effects as
ollows. HDL-C was lowered by 10% and TAG was raised by 20% for
ndividuals on lipid-lowering treatment, and glucose was raised by
0% or to a maximum of 126 mg/dL for those on diabetes med-
cations [21] . In the ERF, pairwise partial correlation coeﬃcients
ere generated for each metabolite-trait association, and all anal-
ses were adjusted for age, sex, lipid-lowering medications, and
amily relationship using polygenic in the GenABEL R package [22] .
onferroni-corrected p -values for obesity and dysglycemia were in-
ividually calculated as 0.05/n where n was equal to the number
f metabolites measured in the ERF with available data for the cor-
esponding trait. 
For the longitudinal analyses, single marker associations were
valuated using general linear models (SAS procedure: GLM) with
ach lipid marker as the predictor and longitudinal changes in each
etabolic trait (BMI, glucose, TAG, and HDL-C) as the outcome.
ll models were adjusted for age, sex, cohort, and baseline values
f BMI, glucose, TAG, total cholesterol, and HDL-C. For individuals
ith self-reported use of lipid-lowering or diabetes medications at
ollow-up, values were adjusted as described above. We evaluated
ultimarker associations with longitudinal changes using stepwise
egression with forward selection. Lipid markers with false discov-
ry rate (FDR) < 0.25 in the single-marker analysis were consid-
4 X. Yin, C.M. Willinger and J. Keefe et al. / EBioMedicine 51 (2020) 102520 
Table 1 
Study design and clinical characteristics of FHS samples. 
Clinical characteristics Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 
Obesity ∗ – – – – + + + + 
Dyslipidemia ∗ – – + + – – + + 
Dysglycemia ∗ – + – + – + – + 
Sample size (n) 84 83 84 84 82 84 74 83 
Age (years) 52 ± 14 54 ± 13 52 ± 14 54 ± 15 53 ± 12 54 ± 11 50 ± 14 55 ± 13 
Women (%) 50 49 50 50 50 50 57 49 
BMI (kg/m 2 ) 24.5 ± 2.8 25.0 ± 2.7 25.9 ±2.7 26.6 ±2.3 32.4 ± 2.3 35.9 ± 5.1 35.4 ±4.8 34.9 ± 4.9 
HDL-C (mg/dL) 65 ± 18 62 ± 15 45 ± 11 44 ± 14 61 ± 13 58 ± 13 42 ± 10 42 ± 10 
TAG (mg/dL) 81 ± 26 84 ± 26 167 ± 115 175 ± 91 92 ± 28 95 ± 29 165 ± 77 202 ± 148 
Glucose (mg/dL) 92 ± 5 107 ± 15 92 ± 5 107 ± 7 93 ± 4 109 ± 7 93 ± 5 122 ± 37 
∗ ( + ) and (-) represent the presence and absence, respectively, of obesity, dysglycemia, and dyslipidemia in each of the eight metabolic 
risk factor groups. Obesity was deﬁned as BMI ≥30 kg/m 2 . Dysglycemia was deﬁned as fasting blood glucose ≥100 mg/dL. Dyslipidemia 
was deﬁned as either TAG ≥150 mg/dL or HDL-C < 40 mg/dL in men or < 50 mg/dL in women. 
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n  ered as initial candidates for each trait. A dynamic p -value thresh-
old corresponding to FDR < 0.25 was used for selection at each
step [at step i, p < (0.25 ∗i /154)]. For each trait, an aggregate R 2 
was calculated from the ﬁnal model after forward selection. 
To account for intercorrelations among lipid markers, princi-
pal component analyses were performed for the discovery ( n = 22
principal components) and PESA replication ( n = 13 principal com-
ponents) sets. The number of principal components with eigenval-
ues > 1 was deemed the number of “independent” tests, and Bon-
ferroni correction was applied to account for multiple testing. For
the cross-sectional analyses, the experiment-wide p -value thresh-
old was determined as 0.05/ n where n was equal to the num-
ber of principal components times four primary analyses (three
risk factors plus the eight-group comparison) [23] . This method
yielded a threshold of p < 5.7 ×10 −4 for the FHS [0.05/(4 ×22)].
The same methodology was used to determine the p -value thresh-
old ( p < 5.7 ×10 −4 ) for the longitudinal study, considering the four
primary analyses (one per continuous metabolic trait). 
2.6. Ethics statement 
Informed consent was given by all participants at time of exam
cycle from the FHS. The clinical study protocol was approved by
the Boston University Medical Campus Institutional Review Board. 
3. Results 
3.1. Study sample characteristics 
Table 1 lists the clinical characteristics of the 658 FHS partic-
ipants according to the eight prespeciﬁed combinatorial groups.
By design, mean age and percentage of women were consistent
across all eight groups in the FHS, while by design, BMI, glu-
cose, and lipid levels (HDL-C and TAG) varied. Supplementary Table
1 shows the clinical characteristics of the FHS longitudinal sam-
ple ( n = 554) at the baseline and follow-up examinations. Mean
changes, adjusted for lipid-lowering or hyperglycemia medication-
use, were determined from baseline to follow-up for the four
metabolic traits: 0.6 ±2.6 kg/m 2 for BMI, 0.5 ±20.4 mg/dL for fast-
ing glucose, 3.6 ±10.7 mg/dL for HDL-C, and −0.5 ±84.6 mg/dL for
TAG. 
3.2. Analytical set of potential lipidomic biomarkers 
154 distinct metabolites representing ten classes and subclasses
were measured in the FHS: four ceramides (Cers), 11 cholesteryl
esters (CEs), eight diacylglycerols (DAGs), 21 lysophosphatidyl-
cholines (LPCs), four lysophosphatidylethanolamines (LPEs), 28
phosphatidylcholines (PCs), 11 phosphatidylethanolamines (PEs),ne phosphatidylserine (PS), 26 sphingomyelins (SMs), and 40 tria-
ylglycerols (TAGs). A correlation matrix for all 154 lipid species is
rovided in Supplementary Figure 1. Many metabolite species were
ositively correlated, with the exception of some LPCs and TAGs,
hich were negatively correlated. Fig. 1 provides a ﬂow chart of
he analytical set and how each marker are used for analysis. . 
.3. FHS cross-sectional associations with metabolic risk factors 
Among the aforementioned lipid species, several were cross-
ectionally associated with obesity ( n = 39; Table 2 ), dysglycemia
 n = 8; Table 3 ), and dyslipidemia ( n = 89; Supplementary Table
) in the FHS. Many of the lipid markers for obesity were LPCs
 n = 18; Table 2 ). LPCs, PCs, and LPEs were inversely associated,
hile SMs, TAGs, and DAGs were directly correlated with obe-
ity ( Table 2 ). Eight lipids were associated with dysglycemia; LPCs
 n = 5, Table 3 ) were inversely associated, while SMs and Cer ( n = 3,
able 3 ) were directly correlated with dysglycemia. The SM and Cer
pecies are dihydrosphingolipids (dhSLs), which have backbones
omprised of sphinganine (d18:0) rather than sphingosine (d18:1)
s is the case for sphingolipids (SLs). Supplementary Table 4 lists
ll 89 lipid species associated with dyslipidemia (direct = 63, in-
erse = 26) along with their corresponding replication results. We
urther analyzed the metabolites by class; results are shown in
upplementary Figures 2, 3, 4, and 5 for obesity, dysglycemia,
ow vs. high HDL-C, and high vs. low TAG, respectively. Despite
irectional consistency, the majority of the associations between
etabolite classes representing several individual lipid species and
etabolic risk factors were not statistically signiﬁcant, likely due
o the broad diversity of individual metabolite species represented.
.4. External replication 
Independent external replication of all FHS cross-sectional
etabolite associations with obesity and dysglycemia was sought
n the ERF study, SAFHS, and PESA. Of the 39 metabolites that
ere cross-sectionally associated with obesity in the FHS, a total
f 32 had available data for replication. Of these 32 metabolites, 28
ere signiﬁcantly associated with obesity at p < 1.56E-03 (0.05/32)
 Table 2 , Supplementary Table 2). Of the eight metabolites cross-
ectionally associated with dysglycemia in the FHS, six had avail-
ble data for replication. Of these six metabolites, ﬁve were asso-
iated with dysglycemia at p < 8.3E-03 (0.05/6) ( Table 3 , Supple-
entary Table 3). 
.5. Associations with longitudinal changes in metabolic traits 
We identiﬁed several lipid species associated with longitudi-
al changes in BMI ( n = 4), glucose ( n = 4), and HDL-C ( n = 1)
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Table 2 
Cross-sectional lipid associations with obesity in FHS. 
Lipid species Class Estimated β∗ SE P -value † Replication # 
LPC 17:0 LPC −0.618 0.072 1.05E-16 √ 
LPC 18:2 LPC −0.524 0.069 1.67E-13 √ 
LPC 18:0p LPC −0.503 0.070 2.28E-12 √ 
LPC 18:1 LPC −0.510 0.072 3.89E-12 √ 
LPC 18:0e LPC −0.503 0.071 3.95E-12 √ 
PC 16:2e PC −0.448 0.067 4.52E-11 
SM 36:0 SM 0.493 0.075 7.81E-11 
LPC 22:5 LPC −0.462 0.073 5.08E-10 
PC 40:8 PC −0.460 0.074 8.80E-10 
LPC 17:1 LPC −0.447 0.073 1.97E-09 √ 
LPC 15:0 LPC −0.439 0.076 1.06E-08 √ 
LPC 18:0 LPC −0.423 0.074 1.34E-08 √ 
LPC 22:6 LPC −0.427 0.075 2.26E-08 √ 
PC 34:0 PC −0.407 0.074 6.45E-08 
LPC 16:0 LPC −0.387 0.072 1.31E-07 √ 
LPC 20:4 LPC −0.365 0.071 3.30E-07 √ 
LPC 18:1e LPC −0.373 0.073 4.35E-07 √ 
TAG 50:1 TAG 0.329 0.065 6.44E-07 
√ 
TAG 50:2 TAG 0.323 0.065 7.76E-07 
√ 
LPC 18:3 LPC −0.369 0.076 1.40E-06 
PC 38:3 PC 0.362 0.075 1.66E-06 
√ 
SM (d18:0/24:0) SM 0.347 0.075 4.86E-06 
LPE 16:0 LPE −0.352 0.078 7.17E-06 √ 
TAG 48:0 TAG 0.310 0.069 8.65E-06 
√ 
LPE 18:1 LPE −0.343 0.077 1.04E-05 √ 
LPC 16:0e LPC −0.317 0.072 1.16E-05 √ 
LPC 16:1e LPC −0.310 0.072 1.86E-05 √ 
DAG 32:0 DAG 0.280 0.067 3.04E-05 
LPC 18:2e LPC −0.299 0.074 5.24E-05 √ 
TAG 48:1 TAG 0.276 0.069 6.40E-05 
√ 
PC 40:7 PC −0.302 0.075 6.85E-05 √ 
PC 36:3e PC −0.283 0.072 1.01E-04 √ 
LPC 20:5 LPC −0.296 0.076 1.04E-04 
TAG 52:1 TAG 0.251 0.066 1.51E-04 
√ 
LPE 18:2 LPE −0.276 0.078 4.26E-04 √ 
PC 34:1e PC −0.249 0.071 4.58E-04 
PC 36:2 PC −0.270 0.077 4.85E-04 √ 
PC 36:0 PC −0.270 0.077 5.13E-04 √ 
DAG 34:1 DAG 0.221 0.064 5.48E-04 
∗ Estimated β coeﬃcients represent the mean differences in standardized lipid 
measures between participants with and without obesity. 
† The p -value threshold for signiﬁcance was determined by the Bonferroni 
method and based on the number of principal components. In FHS, the p -value 
threshold was p < 5.7 ×10 −4 [0.05/(22 ×4)]. 
# The p -value threshold for replication in the ERF study, PESA co- 
hort, and SAFHS of the lipid cross-sectional associations with obesity 
was calculated using Bonferroni correction to be 1.56 ×10 −3 (0.05/32). √ 
denotes lipid species that replicated in the ERF study, PESA cohort, or 
SAFHS.Abbreviations: DAG = diacylglycerol; LPC = lysophosphatidylcholine; 
LPE = lysophosphatidylethanolamine; PC = phosphatidylcholine; SM = sphingomyelin; 
TAG = triacylglycerol. 
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Table 3 
Cross-sectional lipid associations with dysglycem
Lipid Species Lipid Class Estimated β
Cer (d18:0/24:0) Cer 0.280 
LPC 18:1e LPC −0.279 
LPC 17:0 LPC −0.271 
SM 36:0 SM 0.275 
LPC 18:0e LPC −0.260 
LPC 16:1e LPC −0.254 
SM (d18:0/24:0) SM 0.265 
LPC 18:0p LPC −0.244 
∗ Estimated β coeﬃcients represent the mean 
between participants with and without dysglycem
† The p -value threshold for signiﬁcance in FHS
Bonferroni method [0.05/(22 ×4)]. 
# The p -value threshold for replication in the 
lipid cross-sectional associations with dysglycem
tion to be 8.33 ×10 −3 (0.05/6). √ denotes lipid sp
PESA.Abbreviations: Cer = ceramide; LPC = lysoph Table 4 ). LPCs 16:0, 18:0, 16:0e, and 22:5 were inversely associ-
ted with change in BMI [follow-up minus baseline]. These four
PCs were also inversely associated with BMI in the cross-sectional
nalyses. LPC 18:1 and PC 36:2 were inversely associated with
hange in glucose, and SM 36:0 and SM (d18:0/24:0) were di-
ectly associated with change in glucose. Both SMs were also di-
ectly associated with dysglycemia in the cross-sectional analyses.
M (d18:2/24:1), which was inversely associated with dyslipidemia
n cross-sectional analysis, was directly associated with longitudi-
al change in HDL-C. 
In multimarker analyses, we identiﬁed multimarker panels as-
ociated with longitudinal changes in metabolic traits ( Table 5 ).
he BMI multimarker consisted of LPC 16:0, which explained 2.9%
f the variation in longitudinal change in BMI (baseline BMI ex-
lained 2.7%). SM 36:0 and DAG 36:2 were retained in the ﬁnal
lucose model, together accounting for 6.1% of the variation in
hange in glucose (baseline glucose explained 22.1%). The HDL-C
odel contained SM (d18:2/24:1), LPC 20:3, and PS 36:0. This mul-
imarker panel explained 8.4% of the variation in change in HDL-
 (baseline HDL-C explained 3.2%). LPC 18:3, SM (d18:1/16:0), and
er (d18:1/24:1) were retained in the ﬁnal TAG model. These lipids
ccounted for 8% of the variation in change in TAG (baseline TAG
xplained 20.7%). 
. Discussion 
Associations between plasma lipid classes and metabolic risk
actors have been reported [24–29] , but many of these studies
ere limited to single site studies with small numbers of lipid
pecies or case-control analyses. We used liquid chromatography-
andem mass spectrometry to detect cross-sectional and longitudi-
al lipidomic signatures of key metabolic risk factors. Our cross-
ectional lipidomic signatures of obesity and dysglycemia were
ighly replicable in external studies and highlight two lipid classes
s biomarkers of metabolic risk: lysoglycerophospholipids (LGPLs)
nd sphingolipids (SLs). 
.1. Lysoglycerophospholipid markers of metabolic traits 
Cross-sectional and longitudinal analyses of obesity/BMI and
ysglycemia/fasting blood glucose identiﬁed signiﬁcant associa- 
ions with LGPLs, which are generated along with a free fatty
cid by phospholipase-mediated hydrolysis of glycerophospholipids
GPLs; supplementary ﬁgure 6c) [30] . The predominant LGPL in
ur results was lysophosphatidylcholine (LPC). We identiﬁed in-
erse cross-sectional associations between all LPCs and obesity
 n = 18; Table 2 ). Fifteen (83%) of these associations replicated inia in FHS. 
∗ SE P -value † Replication # 
0.070 6.59E-05 
0.073 1.50E-04 
√ 
0.073 1.98E-04 
√ 
0.075 2.43E-04 
0.071 2.80E-04 
√ 
0.072 4.48E-04 
√ 
0.075 4.79E-04 
0.070 5.48E-04 
√ 
differences in standardized lipid measures 
ia. 
 ( p < 5.7 ×10 −4 ) was determined by the 
ERF study, PESA cohort, and SAFHS of the 
ia was calculated using Bonferroni correc- 
ecies that replicated in the ERF, SAFHS, or 
osphatidylcholine; SM = sphingomyelin. 
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Table 4 
Single marker associations with longitudinal changes in metabolic risk factors. 
Change in metabolic trait Lipid species Lipid class Estimated β∗ SE P -value † FDR Partial R 2 
BMI LPC 16:0 LPC −0.57 0.14 6.7E-05 0.01 0.029 
LPC 18:0 LPC −0.50 0.13 1.7E-04 0.01 0.026 
LPC 16:0e LPC −0.44 0.12 4.2E-04 0.02 0.023 
LPC 22:5 LPC −0.45 0.13 4.3E-04 0.02 0.023 
Glucose SM 36:0 SM 3.71 0.91 5.0E-05 0.01 0.030 
LPC 18:1 LPC −3.37 0.93 2.9E-04 0.02 0.024 
SM (d18:0/24:0) SM 3.34 0.92 3.2E-04 0.02 0.024 
PC 36:2 PC −2.97 0.85 5.2E-04 0.02 0.022 
HDL-C SM (d18:2/24:1) SM 2.61 0.55 2.8E-06 0.00 0.040 
∗ Estimated β coeﬃcients represent the mean differences in longitudinal change (native units) in the stated metabolic 
trait per one standard deviation difference in lipid measures. 
† The p -value threshold for signiﬁcance ( p < 5.7 ×10 −4 ) was determined by the Bonferroni method 
[0.05/(22 ×4)].Abbreviations: LPC = lysophosphatidylcholine; PC = phosphatidylcholine; SM = sphingomyelin.Lipids also 
associated in cross-sectional analysis with the corresponding metabolic risk factor are shown in bold . 
Table 5 
Multimarker associations with longitudinal changes in metabolic risk factors. 
Change in metabolic trait Parameter Estimated β∗ SE P -value † R [2] 
BMI Baseline BMI −0.08 0.02 1E-04 0.027 
Baseline Covariates ‡ 0.051 
LPC 16:0 −0.56 0.14 < 1.0E-04 0.029 
Multi-Metabolite Panel 0.029 
Glucose Baseline Glucose −0.53 0.04 < 1.0E-04 0.221 
Baseline Covariates ‡ 0.289 
SM 36:0 4.05 0.90 < 1.0E-04 0.036 
DAG 36:2 −4.58 1.23 2.0E-04 0.025 
Multi-Metabolite Panel 0.061 
HDL- 
C 
Baseline HDL-C −0.15 0.04 < 1.0E-04 0.032 
Baseline Covariates ‡ 0.097 
SM (d18:2/24:1) 2.67 0.57 < 1.0E-04 0.042 
LPC 20:3 1.60 0.50 1.6E-03 0.020 
PS 36:0 −1.60 0.48 9.0E-04 0.022 
Multi-Metabolite Panel 0.084 
TAG Baseline TAG −0.57 0.05 < 1.0E-04 0.207 
Baseline Covariates ‡ 0.260 
LPC 18:3 −12.75 3.61 4.0E-04 0.023 
SM (d18:1/16:0) −21.18 5.05 < 1.0E-04 0.032 
Cer (d18:1/24:1) 15.91 4.24 2.0E-04 0.026 
Multi-Metabolite Panel 0.080 
∗ Estimated β coeﬃcients represent the mean differences in longitudinal change (native units) in the 
stated metabolic trait per one standard deviation difference in lipid measures. 
† A dynamic p -value threshold for entrance into the model was deﬁned based on FDR < 0.25 [at step 
i, p < (0.25 ∗i )/154]. 
‡ Baseline covariates were as follows: age; sex; cohort; batch; and baseline values for total 
cholesterol, HDL-C, glucose, and BMI.Abbreviations: LPC = lysophosphatidylcholine; DAG = diacylglycerol; 
PS = phosphatidylserine; SM = sphingomyelin; Cer = ceramide.Lipids also signiﬁcant in individual longitu- 
dinal associations are shown in italics . 
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p  the ERF and SAFHS (Supplementary Tables 2 and 3). Four of the
18 LPCs cross-sectionally associated with obesity in the FHS were
also associated with longitudinal changes in BMI ( Table 4 ). Five of
the LPCs associated with obesity cross-sectionally in the FHS were
also inversely associated with dysglycemia (Supplementary Table
5), and all ﬁve of these associations replicated. Nine phosphatidyl-
cholines (PCs) were associated with obesity ( Table 2 ) – all show-
ing inverse associations, with the exception of PC (38:3), which
showed a positive association with obesity ( β = 0.36, P = 1.7E-06;
Table 2 ). This association replicated in the ERF, and prior work has
shown PC (38:3) to be positively associated with CVD [31] and en-
riched in atherosclerotic plaques [32] . Of the nine PCs associated
with obesity, seven were available for replication and ﬁve (71%),
including PC (38:3), replicated (Supplementary Table 2). Lysophos-
phatidylethanolamine (LPE), another LGPL class detected by our
lipid-proﬁling platform, was inversely associated with obesity in
the FHS ( Table 2 ); all three LPEs associated with obesity in the FHS
replicated (Supplementary Table 2). Overall, LGPLs were inverselyassociated with metabolic risk factors. e  
r  Recent evidence, which has implicated LGPLs in essential sig-
aling processes [33] , highlights the potential utility of these lipid
lasses as novel biomarkers of cardiometabolic risk. LPCs are the
ost well-characterized and abundant LGPL in human plasma
125–143 μM in healthy individuals) [34] , and circulating levels are
etermined by their generation via two pathways – 1) transfer of a
atty acid from PC to cholesterol by lecithin-cholesterol acyltrans-
erase (LCAT; supplementary Figure 6d), and 2) phospholipase A 2 
PLA 2 )-mediated hydrolysis of PC [35] (Supplementary Figure 6c,
ottom) and clearance via transporters such as albumin and alpha-
 acid glycoprotein [34] . While LPCs have been found to be ele-
ated in atherosclerotic plaques [32] , and thus might be expected
o positively correlate with metabolic risk factors, we found inverse
ssociations between LPCs and obesity and dysglycemia ( Tables 2 ,
 ). This seemingly counterintuitive ﬁnding for LPCs, however, has
een demonstrated for CVD [ 31 , 36 ] and perhaps reﬂects an in-
rease in LPC catabolism or a decrease in its generation in such
hysiological states. Indeed, individuals with coronary artery dis-
ase have been shown to have lower LCAT activity [37] , and three
ecent studies found reduced plasma LPC levels in obese patients
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v 24 , 25 , 13 ]. Furthermore, higher levels of circulating LPC could re-
ect a lower rate of atherogenic lysophosphatidic acid produc-
ion via autotaxin-mediated LPC hydrolysis, thus conferring a net
rotective effect on CVD [38] . Therefore, in conjunction with re-
ent epidemiological evidence associating dairy consumption with
hanges in circulating LPC 17:0 [39] , an abundance of genetic, epi-
emiologic, functional, and biochemical data implicating LPCs in
VD suggest that mechanistically understanding the enzyme kinet-
cs and complexities of LPC metabolism may highlight promising
herapeutic targets. 
.2. Sphingolipid markers for metabolic traits 
Sphingolipids, comprised of Cers, SMs, and their reduced
orms (dhCers and dhSMs), were positively associated with obe-
ity ( Table 2 ) and dysglycemia ( Table 3 ). The two dhSMs posi-
ively associated with obesity – SM 36:0 and SM (d18:0/24:0) –
ere also positively associated with dysglycemia, along with Cer
d18:0/24:0). Cer (d18:0/24:0) shares the same sphingosine back-
one and fatty acyl side chains as SM (d18:0/24:0) such that
he two are inter-convertible via the enzymatic actions of sphin-
omyelin synthase (SMS; Cer → SM) and sphingomyelinase (SMase;
M → Cer). Of note, SM 36:0 and SM (d18:0/24:0) were also associ-
ted with longitudinal change in glucose ( Table 4 ). 
Sphingolipids, which are characterized by a sphingosine back-
one, are synthesized de novo from the condensation of palmitoyl-
oA and serine by serine palmitoyltransferase [40] , with the re-
ulting dhCer being oxidizable by dihydroceramide desaturases
Des) to Cer. Sphingolipids are integral structural constituents of
ipid membranes and are involved in cell signaling and apoptosis
 41 , 42 ], with SMs being the most prevalent SLs in human plasma
hat can be derived from Cers via SMS, releasing a DAG in the
rocess [ 41 , 43 ] (Supplementary Figure 6a). Sphingomyelin inhibits
ipoprotein lipase (LPL)-catalyzed hydrolysis of TAG [44] and LCAT-
atalyzed esteriﬁcation of cholesterol [45] (Supplementary Figure
b), and individuals with SMase deﬁciency (Niemann-Pick disease)
ave low plasma HDL-C levels [46] due to SM-mediated inhibition
f cholesterol eﬄux. Sphingomyelin accumulation has been asso-
iated with T2DM [47] and observed in mouse models of insulin
esistance [ 4 8 , 4 9 ] as well as in the skeletal muscle and serum of
bese, insulin-resistant humans [ 27 , 50 , 51 ]. 
Prior studies have shown plasma SM levels to predict coro-
ary artery disease risk, possibly due to their strong correlations
ith apolipoprotein B (apoB) and TAG levels [52] . Indeed, the
M content of apoB-containing or TAG-rich lipoproteins is higher
han that in HDL [53] , and hydrolysis of LDL-associated SM to Cer
auses LDL particle aggregation and macrophage foam cell forma-
ion [ 54 , 55 ], which are two hallmarks of atherosclerosis. Recent
tudies have suggested that Cer provides additional prognostic util-
ty for CVD beyond that from LDL-C [56] – perhaps because it acts
s a proxy to standardize changes in LDL-C mass by changes in
poB concentration, which is the biological determinant of athero-
enicity of a high LDL-C level [57] . Interestingly, a missense muta-
ion (rs267738) in the CERS2 gene, which encodes the enzyme ce-
amide synthase that is responsible for biosynthesis of very long-
hain Cer (C22/C24/C24:1), is also associated with hemoglobin A1c
evels [58] , and functional studies have shown that CerS2 haploin-
uﬃciency in mice results in insulin resistance and non-alcoholic
atty liver disease [59] , possibly due to a compensatory increase
n atherogenic Cer-16. Of note, several dietary intervention studies
ave demonstrated that improved diet quality blunts the associa-
ion between Cer and CVD [60] , perhaps due to the dependence of
er synthesis on dietary intake of saturated fats [61] . Nonetheless,
he most direct evidence comes from mouse knockout studies in
hich genetic ablation of key enzymes in Cer synthesis mitigates
therosclerosis [62] , insulin resistance [63] , and T2DM [64] amongther metabolic-related disease phenotypes. Taken together with
ur results, there is an abundance of evidence for Cers and SMs as
arkers of obesity and dysglycemia risk. 
We acknowledge several limitations of our study. First, the ef-
ect sizes and metabolite species differed among the FHS and repli-
ation cohorts, despite directional consistency in the replicable
etabolites. These discrepancies were in part due to differences in
nvironmental exposures (i.e. smoking) [ 13 , 65 ] as well as discrep-
ncies in lipidomic and analytical techniques across studies. More-
ver, some lipids were unavailable for replication. Even considering
hese limitations, however, consistent relationships were observed,
hus reinforcing the robustness of the replicated results. Second,
he longitudinal changes in mean TAG levels ( < 1 mg/dL over six-
ears of follow up) were small and not of a magnitude to confer
linical consequences. Third, our lipid quantiﬁcation methods did
ot allow for the separation of isomeric species and thus multiple
somers could have contributed to each lipid measurement. Fourth,
he low replication rate for sphingolipids was partially due to the
act that many of the sphingolipids quantiﬁed in the FHS via liquid
hromatography tandem mass spectrometry were not measured in
he replication cohorts, which used different lipidomic platforms.
inally, larger-scale, multi-site epidemiological studies as well as
unctional experiments are needed to conﬁrm and extend the ﬁnd-
ngs of this investigation. 
. Conclusions 
We identiﬁed numerous lipid species that were associated with
etabolic risk factors cross-sectionally and with their longitudinal
hanges. Of note, we demonstrated robust and replicable associ-
tions of lysoglycerophospholipids and dihydrosphingolipids with 
besity and dysglycemia. Taken together with biological evidence
nd prior interventional and functional studies, we hypothesize
hat the lipid species identiﬁed in this study may serve as key
echanistic drivers of metabolic dysregulation and can lay the
roundwork for future studies to explore their potential therapeu-
ic relevance. 
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